CoChat

Therapeutic peptides: current applications and future directions

Open access
Wang, Lei, Wang, Nanxi, Zhang, Wenping, Cheng, Xurui, Yan, Zhibin, Shao, Gang, Wang, Xi, Wang, Rui, Fu, Caiyun · 2022 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 535 of the 542 references it cites were found in a registry or an index.

Abstract

Peptide drug development has made great progress in the last decade thanks to new production, modification, and analytic technologies. Peptides have been produced and modified using both chemical and biological methods, together with novel design and delivery strategies, which have helped to overcome the inherent drawbacks of peptides and have allowed the continued advancement of this field. A wide variety of natural and modified peptides have been obtained and studied, covering multiple therapeutic areas. This review summarizes the efforts and achievements in peptide drug discovery, production, and modification, and their current applications. We also discuss the value and challenges associated with future developments in therapeutic peptides.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-00904-4

Cites

535 of 535 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Top-selling non-insulin peptides worldwide in 2019. Data analysis according to Njardarson’s group27
Fig. 1 Top-selling non-insulin peptides worldwide in 2019. Data analysis according to Njardarson’s group27CC BY · PubMed Central
Fig. 2 Peptides versus small molecules and biologics. Comparison of advantages and drawbacks between peptides and small molecules or biologics
Fig. 2 Peptides versus small molecules and biologics. Comparison of advantages and drawbacks between peptides and small molecules or biologicsCC BY · PubMed Central
Fig. 3 Structure of human insulin and human insulin-derived drugs. Structure of human insulin (left, PDB: 1XDA). Modifications on its residues (B-Chain: B3: Asn, B28: Pro, B29: Lys; A-Chain: A21: Asn) resulted in several short- and long-acting insulin drugs (right, see table)
Fig. 3 Structure of human insulin and human insulin-derived drugs. Structure of human insulin (left, PDB: 1XDA). Modifications on its residues (B-Chain: B3: Asn, B28: Pro, B29: Lys; A-Chain: A21: Asn) resulted in several short- and long-acting insulin drugs (right, see table)CC BY · PubMed Central
Fig. 4 Sequences and structures of natural hormones GLP-1 and GnRH and their peptidomimetic drugs. a Liraglutide is a GLP-1 derived peptide drug, modified on 26th residue (K) of its natural sequence. b Leuprolide and degarelix are modified from the natural sequence of GnRH
Fig. 4 Sequences and structures of natural hormones GLP-1 and GnRH and their peptidomimetic drugs. a Liraglutide is a GLP-1 derived peptide drug, modified on 26th residue (K) of its natural sequence. b Leuprolide and degarelix are modified from the natural sequence of GnRHCC BY · PubMed Central
Fig. 5 Sequences and structures. Exenatide (a) and lugdunin (b)
Fig. 5 Sequences and structures. Exenatide (a) and lugdunin (b)CC BY · PubMed Central
Fig. 6 A general process of solid-phase peptide synthesis (SPPS) with Fmoc protected amino acids (Fmoc-AA-OH). Fmoc-SPPS consists a cycle of coupling Fmoc-AA-OH to a solid polymeric resin and deprotection of Fmoc to liberate amino groups. The whole process can be carried out in a sieve reactor till the final peptide is cleaved from the resin
Fig. 6 A general process of solid-phase peptide synthesis (SPPS) with Fmoc protected amino acids (Fmoc-AA-OH). Fmoc-SPPS consists a cycle of coupling Fmoc-AA-OH to a solid polymeric resin and deprotection of Fmoc to liberate amino groups. The whole process can be carried out in a sieve reactor till the final peptide is cleaved from the resinCC BY · PubMed Central
Fig. 7 Strategies of peptide cyclization and stabilization of α-helices, β-sheets, and β-strands. The establishment of intramolecular cross-links can stabilize different secondary structures of peptides. Side chain cross-links between i and i + 4 or/and i + 7 and hydrogen bond surrogate cross-links can stabilize α-helices. Side chain-to-side chain, head-to-tail, and side chain-to-tail cyclization can stabilize turn, loop and β structures (β-sheets and β-strands). The D-Pro-L-Pro scaffold can specifically stabilize antiparallel β-hairpins
Fig. 7 Strategies of peptide cyclization and stabilization of α-helices, β-sheets, and β-strands. The establishment of intramolecular cross-links can stabilize different secondary structures of peptides. Side chain cross-links between i and i + 4 or/and i + 7 and hydrogen bond surrogate cross-links can stabilize α-helices. Side chain-to-side chain, head-to-tail, and side chain-to-tail cyclization can stabilize turn, loop and β structures (β-sheets and β-strands). The D-Pro-L-Pro scaffold can specifically stabilize antiparallel β-hairpinsCC BY · PubMed Central
Fig. 8 Scheme of genetic code expansion. Genetic code expansion enables the site-specific incorporation of an noncanonical amino acid (shown in green filled circle) into a growing peptide chain by suppressing an unique codon (e.g., amber stop codon)
Fig. 8 Scheme of genetic code expansion. Genetic code expansion enables the site-specific incorporation of an noncanonical amino acid (shown in green filled circle) into a growing peptide chain by suppressing an unique codon (e.g., amber stop codon)CC BY · PubMed Central
Fig. 9 PEGylation of therapeutic peptides and proteins via genetic code expansion. Azide or acetyl groups are introduced into therapeutic peptides and proteins by genetic code expansion to allow downstream PEGylation modifications
Fig. 9 PEGylation of therapeutic peptides and proteins via genetic code expansion. Azide or acetyl groups are introduced into therapeutic peptides and proteins by genetic code expansion to allow downstream PEGylation modificationsCC BY · PubMed Central
Fig. 10 Non-canonical amino acids described in this review
Fig. 10 Non-canonical amino acids described in this reviewCC BY · PubMed Central
Fig. 11 Mechanisms of GLP-1 and GLP-1RA peptide drugs in regulation of T2DM. GLP-1 and GLP-1RA peptide drugs treat T2DM by regulating multiple organs functions, such as reducing gastric emptying and gastric acid secretion, reducing appetite, promoting cardiac glucose utilization, accelerating renal natriuresis and diuresis, minimizing glucose production in the liver and increasing insulin secretion in the pancreas
Fig. 11 Mechanisms of GLP-1 and GLP-1RA peptide drugs in regulation of T2DM. GLP-1 and GLP-1RA peptide drugs treat T2DM by regulating multiple organs functions, such as reducing gastric emptying and gastric acid secretion, reducing appetite, promoting cardiac glucose utilization, accelerating renal natriuresis and diuresis, minimizing glucose production in the liver and increasing insulin secretion in the pancreasCC BY · PubMed Central
Fig. 12 Mechanism of natriuretic peptide (NPs) regulation. Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) regulate cardiac and vascular homeostasis through binding to their receptors (NPR-A, -B and -C) to reduce sympathetic tone, fibrosis and renin secretion to treat cardiovascular diseases
Fig. 12 Mechanism of natriuretic peptide (NPs) regulation. Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) regulate cardiac and vascular homeostasis through binding to their receptors (NPR-A, -B and -C) to reduce sympathetic tone, fibrosis and renin secretion to treat cardiovascular diseasesCC BY · PubMed Central
Fig. 13 The structure and sequence of GLP-2 (PDB: 2L63)325
Fig. 13 The structure and sequence of GLP-2 (PDB: 2L63)325CC BY · PubMed Central
Fig. 14 Application of peptides in tumor therapy. a Screening and identification of peptide candidates from chemically synthesized peptide library and phage library. b Using radiolabeled, dye-labeled, or other designed peptides as probes for tumor diagnosis and imaging. c Application of peptide-conjugated nanomaterials in tumor therapy. d Using peptide vaccine and targeting peptides in tumor immunotherapy and targeted therapy
Fig. 14 Application of peptides in tumor therapy. a Screening and identification of peptide candidates from chemically synthesized peptide library and phage library. b Using radiolabeled, dye-labeled, or other designed peptides as probes for tumor diagnosis and imaging. c Application of peptide-conjugated nanomaterials in tumor therapy. d Using peptide vaccine and targeting peptides in tumor immunotherapy and targeted therapyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 535 references

Research works printed but not linked: 4

  1. Miao, J. Y. et al. Designing cyclic-peptide inhibitors of protein-protein interactions by mimicking hot loops. Abstr Pap Am Chem S. 256, 434 (2018).
  2. Neukirchen, S. et al. Cyclic peptides for targeting helical protein-protein interactions. J. Pept. Sci. 22, S50–S52 (2016).
  3. Bogomolov, P. et al. A proof-of-concept Phase IIa clinical trial to treat chronic HBV/HDV with the entry inhibitor myrcludex B. Hepatology 64, 121a–121a (2016).
  4. Loglio, A. et al. Myrcludex monotherapy in compensated cirrhotics with delta hepatitis: safety and effectiveness beyond two years of treatment in a real-life setting. Hepatology 72, 624a–624a (2020).

Cited by

See all 2,131

Metadata

Authors
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C.
Affiliations
  • Zhejiang Sci-Tech University (CN)
  • Nanjing University of Chinese Medicine (CN)
  • Hangzhou Medical College (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
  • Wang, Rui
  • Fu, Caiyun
Venue
Signal Transduction and Targeted Therapy
Published
2022-02-14
Volume
7
Issue
1
Pages
48-48
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4212959738
Cited by
2,131
References
542
Citations by year
2026: 477 · 2025: 666 · 2024: 537 · 2023: 336 · 2022: 111
FWCI
42.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lanzhou University Institutional Repository (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81770176)
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
Keywords
peptide therapeutics, peptide drug development, peptide drug discovery, peptide modification, peptide production, peptide delivery, peptide design, natural peptides
MeSH terms
Peptides, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic peptides: current applications and future directions. https://app.cochat.ai/papers/10.1038/s41392-022-00904-4
The paper
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022). Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-00904-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.